Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CK Life Sciences International HoldingsCKLSF 34 Days Sales Outstanding is 71.69 as of Jun. 2026, which is 14% above its 10-year median of 63.05. GuruFocus rates CKLSF with a GF Score™ of 34/100 and a GF Value™ of $0.10 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 835 Biotechnology companies, CK Life Sciences International Holdings ranks worse than 51.38% on this metric.
CKLSF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.26 Med: 63.05 Max: 76.86
Current: 70.35
During the past 13 years, CK Life Sciences International Holdings's highest Days Sales Outstanding was 76.86. The lowest was 54.26. And the median was 63.05.
CKLSF's Days Sales Outstanding is ranked worse than 51.38% of 835
companies
in the Biotechnology industry
Industry Median: 68.94
vs CKLSF: 70.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Days Sales Outstanding Chart
CK Life Sciences International Holdings Annual Data
CKLSF vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CK Life Sciences International Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where CK Life Sciences International Holdings's Days Sales Outstanding falls into.
CK Life Sciences International Holdings Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings (CKLSF) has a Days Sales Outstanding of 71.69 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CK Life Sciences International Holdings and its competitors. This is 14% above median its historical median of 63.05. Over the past decade, CK Life Sciences International Holdings' Days Sales Outstanding has ranged from 54.26 to 76.86. According to the industry distribution chart, CK Life Sciences International Holdings ranks #429 out of 835 companies in the Biotechnology industry, placing it in the top 51.4%.
Is CK Life Sciences International Holdings' Days Sales Outstanding too high?
CK Life Sciences International Holdings' current Days Sales Outstanding of 71.69 is 14% above median its 10-year median of 63.05. Over the past 10 years, this metric has ranged from a low of 54.26 to a high of 76.86. The Biotechnology industry median Days Sales Outstanding is 68.94. CK Life Sciences International Holdings' value of 71.69 is 4% above this industry median. Based on the distribution chart, CK Life Sciences International Holdings ranks #429 out of 835 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #429 out of 835 companies for Days Sales Outstanding. This places CK Life Sciences International Holdings in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. CK Life Sciences International Holdings' value of 71.69 is 4% above this benchmark. Historically, CK Life Sciences International Holdings' own Days Sales Outstanding has ranged from 54.26 to 76.86 over the past decade. While the company's 10-year median is 63.05 vs. the industry median of 68.94, CK Life Sciences International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CK Life Sciences International Holdings's current Days Sales Outstanding of 71.69 is 4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current Days Sales Outstanding is 71.69, which is 14% above median its own 10-year median of 63.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
Based on GuruFocus' analysis, CK Life Sciences International Holdings (CKLSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.07 — trading 30.7% below its estimated fair value. The current Days Sales Outstanding is 71.69, which is 14% above median its 10-year median of 63.05 and 4% above the Biotechnology industry median of 68.94. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current Days Sales Outstanding is 71.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.07 is trading 30.7% below its estimated GF Value™ of $0.10.
GuruFocus considers CK Life Sciences International Holdings to be Possible Value Trap.
Key valuation signals for CKLSF:
Days Sales Outstanding: 71.69 (14% above median its 10-year median of 63.05)
GF Value™: $0.10 vs. price of $0.07 (30.7% below fair value)
Industry Position: 4% above the Biotechnology median (#429 of 835)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score
Get the complete analysis for CKLSF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
